Leah Lawrence, Author at Cancer Therapy Advisor

Comparable Outcomes With and Without Neoadjuvant Therapy in High-Risk Melanoma

By

Leah Lawrence

March 22, 2023

Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.

Breast Cancer

Low-Dose Tamoxifen Reduces Risk of Breast Cancer Long-Term

By

Leah Lawrence

March 21, 2023

Low-dose tamoxifen reduces the risk of breast cancer among patients with intraepithelial neoplasia for several years, data suggest.

Gynecologic Cancer

Postoperative AEs Delay Chemotherapy but Do Not Affect Survival in Ovarian Cancer

By

Leah Lawrence

March 20, 2023

Postoperative adverse events can delay chemotherapy but do not affect survival outcomes in patients with platinum-sensitive, recurrent ovarian cancer, a study suggests.

Multiple Myeloma

Infections Observed in Half of MM Patients Treated With Bispecific Antibodies

By

Leah Lawrence

March 17, 2023

Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.

Lung Cancer

Immunotherapy May Increase the Risk of Treatment Discontinuation in SCLC

By

Leah Lawrence

March 16, 2023

Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.

Breast Cancer

10-Year Data Support Use of Adjuvant Paclitaxel-Trastuzumab in HER2+ Breast Cancer

By

Leah Lawrence

March 14, 2023

Updated results support the use of adjuvant paclitaxel and trastuzumab in small, node-negative, HER2-positive breast cancer, according to researchers.